In North Carolina, biotechnology company Jellatech has announced an oversubscribed, $3.5-million seed round as it looks to scale production of bio-identical human, bovine, and porcine collagens from animal-free sources. Such proteins have applications in healthcare, personal care, biomedical research, and the food and beverage industries.
“We are very excited to bring in new and existing investors, support and capital to realize the mission of our company. We have demonstrated the success of our first proteins and now it is time to scale it up and push our technology and capabilities even further,” Stephanie Michelsen, Jellatech founder and CEO said in a press statement.
This Seed Round was led by Nordic-based byFounders. Participating investors also included Milano Investment Partners, Joyful VC, Siddhi Capital, and Blustein.